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dDITORIAL COMMENT
irolimus-Eluting Stents:
oes a Great Stent Still
eed a Good Interventionalist?*
oseph P. Carrozza, JR, MD FACC
oston, Massachusetts
he history of interventional cardiology has been an exem-
lar of the old saying: “Two steps forward and one step
ack.” Without a doubt, percutaneous coronary angioplasty
ffered an important therapeutic option intermediate to the
xtremes of medical management and bypass surgery. How-
ver, although balloon angioplasty has been acutely success-
ul in more than 90% of patients, many patients experienced
he new iatrogenic disease of restenosis. Restenosis is a
omplex pathophysiologic process recapitulating many ele-
ents of wound healing such as inflammation, thrombosis,
ellular proliferation, and ground matrix deposition (1).
ltimately, elastic recoil, vessel contraction, and smooth
uscle cell proliferation culminate in flow-limiting luminal
arrowing in 20% to 50% of dilated vessels (2). The use of
ndovascular prostheses (i.e., stents) essentially eliminated
ascular recoil and remodeling, resulting in significant
eductions in restenosis in almost every lesion and patient
ubset. But the price of stenting is an exaggerated prolifer-
tive response commensurate with acute gain. The problem
f in-stent restenosis (ISR) became the “one step back” of
tenting.
See page 1110
Concurrent with the emergence of stenting as the pre-
ominant catheter-based revascularization technique was
he demand for outcomes derived from evidence-based
edicine. Thus, the large randomized trial became a pre-
equisite for acceptance of most conclusions related to
tenting. Catheter-based therapeutics, especially stenting,
ecame one of the most closely studied treatments in
edicine. One consistent paradigm repeatedly validated in
he literature of interventional cardiology was the “bigger is
etter theory” which linked acute angiographic outcome
ith freedom from restenosis (3). This simple concept, as
ell as the empiric findings from intravascular ultrasound
tudies of optimal stenting, clearly established the impor-
ance of the operator in maximizing outcome with this
reakthrough technology.
Despite the emergence of better and more deliverable
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of the JACC or the
merican College of Cardiology.
From the Section of Interventional Cardiology, Beth Israel Deaconess Medicalrenter, Boston, Massachusetts.tents and routine high-pressure dilation, the problem of
SR has remained. Stent placement in diabetic patients,
ong lesions, small vessels, bifurcation stenoses, and in the
resence of end-stage renal disease is associated with a
estenosis rate that may exceed 50% (4). In the U.S. alone,
pproximately 200,000 repeat revascularizations were per-
ormed in 2001 at an annual societal cost of $1.5 billion.
ystemic pharmacotherapy has had little impact on reste-
osis, limited by the inability to deliver therapeutic levels to
he vascular wall without incurring systemic toxicity. While
ntravascular brachytherapy has emerged as a powerful tool
or reducing recurrent restenosis in patients who suffered
SR, it required an additional procedure and mandated
rolonged dual antiplatelet therapy to prevent the risk of
ate stent thrombosis. Clearly, a “preemptive strike” was
eeded. In 2001, Sousa et al. (5) reported that stents which
lute the immunosuppressive macrocyclic lactone rapamycin
educed in-stent neointimal volume by 95%, resulting in
reedom from restenosis in all treated patients. Although
his “First-in-Man” registry consisted of only 45 patients, it
ngendered great enthusiasm that the concept of “targeted
rug delivery” might safely lead to the elimination of the
courge of restenosis.
The larger Randomized Study with the Sirolimus-Coated
x-VELOCITY Balloon-Expandable Stent in the Treat-
ent of Patients with De Novo Native Coronary Artery
esions (RAVEL) raised expectations to the highest levels
or the concept of drug-eluting stents by demonstrating a
eduction in angiographic restenosis and target lesion revas-
ularization from 27% to 0% (6). All of the expected terms
ere used to describe this breakthrough technology: “magic
ullet,” “home-run,” and “landmark discovery.” Aside from
eing safe and highly efficacious, drug-eluting stent place-
ent would require no additional training and could be
erformed by any interventional cardiologist qualified to
lace a bare metal coronary stent. Presumably, drug-eluting
tenting might even be easier for the interventionalist
ecause the profound suppression of late loss might negate
he need for optimal stenting. The U.S. pivotal Study of the
irolimus-Eluting Stent in De Novo Native Coronary
esions (SIRIUS) randomized almost 1,100 patients to
reatment with either the sirolimus-eluting Cypher stent
Cordis Corp., Miami Lakes, Florida) or bare metal Bx-
ELOCITY stent (Cordis Corp.) (7). Patients in SIRIUS
ad a higher frequency of diabetes mellitus, longer lesions,
nd greater lesion complexity than patients in the earlier
AVEL. As in RAVEL, in-stent late loss was negligible,
eading to a 91% reduction in ISR from 35% to 3.2%.
owever, tempering the enthusiasm for this new technol-
gy was a somewhat disappointing finding of an 8.9%
estenosis rate when the core angiographic laboratory mea-
ured not only the area within the stent but also the segment
f the vessel encompassing the stent and 5 mm proximal or
istal to its edges. Specifically, these additional in-segment
estenoses were driven primarily by an incomplete suppres-
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March 17, 2004:1116–7 Editorial Commention of proliferation at the proximal edge of the stent,
specially in smaller vessels.
A number of mechanisms were proposed to explain this
henomenon, including inadequate diffusion of sirolimus
eyond the stent edge, inadvertent injury to the proximal
dge from aggressive predilation, inadequate stent-to-lesion
atios, and overexpansion of the ends of the stent delivery
alloon during high-pressure deployment. Clearly, the latter
hree mechanisms are operator- and technique-dependent.
his raised an interesting question: are optimal outcomes
ith drug-eluting stents achieved by a device only, or does
great stent still need a good interventionalist? Specifically,
an changes in operator technique result in restenosis rates
ven lower than those observed in SIRIUS? This hypothesis
as tested in two additional randomized trials, namely
-SIRIUS and C-SIRIUS. In the European E-SIRIUS,
52 patients were randomized to either sirolimus-eluting
tent (SES) or bare metal stent (BMS) (8). Although
atients treated in E-SIRIUS had longer lesions and smaller
essels, binary in-segment restenosis was reduced by 33% in
he drug-eluting stent cohort compared with patients re-
eiving drug-eluting stents in SIRIUS. Unlike SIRIUS
here late loss at the proximal edge was reduced by only
8% with the SES, in E-SIRIUS there was little difference
n the relative reduction in in-stent and in-segment late loss
75% to 80%). These findings are best explained by
mportant differences in technique. Operators in E-SIRIUS
eployed longer stents per lesion length, avoided gaps
etween overlapped stents, and employed direct stenting
i.e., without predilation in 26% of lesions). Effectively, the
perators were careful to avoid leaving injured but unstented
egments of the artery.
If this theory were true, it would place demands on the
perator similar to other interventional techniques. Alter-
atively, the findings in E-SIRIUS might be explained by
hance alone. It is sobering to believe that after publication
f three multicenter, randomized trials comparing the same
reatments, questions remain about optimal usage. Interest-
ngly, neither SIRIUS nor E-SIRIUS corroborated the
ndings of its predecessor studies. In this issue of the
ournal, Schampaert et al. (9) present data from the Cana-
ian randomized trial, C-SIRIUS, the fourth randomized
rial comparing SES to BMS.
At first glance, the C-SIRIUS study appears quite similar
o the E-SIRIUS study except for a smaller sample size.
actors that influence restenosis such as diabetes mellitus,
essel size, and lesion length were similar. However, binary
n-lesion restenosis in the BMS cohort was 52.3%, the
ighest reported for the four trials, suggesting that this was
erhaps the most challenging subset of patients and lesions
f the four randomized trials. Nevertheless, the in-lesion
estenosis rate for patients treated with the SES was only
.3%, lower than that seen in SIRIUS or E-SIRIUS, anbsolute reduction of 50% compared to E-SIRIUS. It is not
urprising that the outcomes in C-SIRIUS more closely
esembled those of E-SIRIUS than of SIRIUS. To an even
reater extent than in E-SIRIUS, the operators placed
tents without predilation, used longer stents resulting in
igher stent to lesion ratios, and post-dilated many stents.
ate loss in C-SIRIUS was actually lower at the edges than
ithin the stent. Thus, the problem of suboptimal suppres-
ion of proliferation at the proximal edge, which drove the
estenosis rate to 8.9% in SIRIUS, has been largely elimi-
ated.
As with RAVEL, SIRIUS, E-SIRIUS, and C-SIRIUS
rovides valuable information regarding this wonderful new
echnology of drug-eluting stents. Moreover, C-SIRIUS
alidates the hypothesis offered in E-SIRIUS, namely that
ptimal outcomes with a potent therapy such as drug-eluting
tents are still operator-dependent. A great stent still needs a
ood interventionalist, or at least one who takes advantage
f the important findings in these four trials. Only in this
ay can we take the two steps forward without the one step
ack.
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